Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines

Cancers

Volumn 3, Issue 3, 2011, Pages 2904-2954

  Wiëers, Gregoire ^a   Demotte, Nathalie ^a   Godelaine, Danièle ^a   van der Bruggen, Pierre ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Anergy; Cancer vaccines; Galectin; Immunosuppression; Tumor infiltrating lymphocytes

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CELL MARKER; CYCLOPHOSPHAMIDE; DACLIZUMAB; DENILEUKIN DIFTITOX; ECALECTIN; FLUOROURACIL; FRESOLIMUMAB; GALECTIN; GALECTIN 1; GALECTIN 3; GLYCOPROTEIN GP 100; HLA ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; IPILIMUMAB; LYMPHOCYTE MEMBRANE RECEPTOR; MDX 1106; PECTASOL; PECTIN; PROGRAMMED DEATH 1 RECEPTOR; REACTIVE OXYGEN METABOLITE; STIBOGLUCONATE SODIUM; T LYMPHOCYTE RECEPTOR; TICILIMUMAB; UNCLASSIFIED DRUG;

AMINO ACID DEFICIENCY; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CLINICAL EFFECTIVENESS; CLONAL ANERGY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LEISHMANIASIS; LEUKOCYTE ACTIVATION; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MALIGNANT MESOTHELIOMA; MELANOMA; METABOLITE; METASTASIS; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; STIMULUS RESPONSE; SYNAPSE VESICLE; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT;

EID: 80053246765     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3032904     Document Type: Review

References (373)

1. Rosenberg, S.A.; Packard, B.S.; Aebersold, P.M.; Solomon, D.; Topalian, S.L.; Toy, S.T.; Simon, P.; Lotze, M.T.; Yang, J.C.; Seipp, C.A.; Simpson, C.; Carter, C.; Bock, S.; Schwartzentruber, D.; Wei, J.P.; White, D.E.; Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 1988, 319, 1676-1680.
2. Dreno, B.; Nguyen, J.M.; Khammari, A.; Pandolfino, M.-C.; Tessier, M.H.; Bercegeay, S.; Cassidanus, A.; Lemarre, P.; Billaudel, S.; Labarriere, N.; Jotereau, F. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol. Immunother. 2002, 51, 539-546.
3. Coulie, P.G.; Karanikas, V.; Lurquin, C.; Colau, D.; Connerotte, T.; Hanagiri, T.; Van Pel, A.; Lucas, S.; Godelaine, D.; Lonchay, C.; Marchand, M.; van Baren, N.; Boon, T. Cytolytic T cell responses of cancer patients vaccinated with a MAGE antigen. Immunol. Rev. 2002, 188, 33-42.
4. Mazzocchi, A.; Belli, F.; Mascheroni, L.; Vegetti, C.; Parmiani, G.; Anichini, A. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int. J. Cancer 1994, 58, 330-339.
5. Coulie, P.G.; Somville, M.; Lehmann, F.; Hainaut, P.; Brasseur, F.; Devos, R.; Boon, T. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer 1992, 50, 289-297.
6. van der Bruggen, P.; Traversari, C.; Chomez, P.; Lurquin, C.; De Plaen, E.; Van den Eynde, B.; Knuth, A.; Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254, 1643-1647.
7. van der Bruggen, P.; Zhang, Y.; Chaux, P.; Stroobant, V.; Panichelli, C.; Schultz, E.S.; Chapiro, J.; Van den Eynde, B.J.; Brasseur, F.; Boon, T. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 2002, 188, 51-64.
8. Parmiani, G.; De Filippo, A.; Novellino, L.; Castelli, C. Unique human tumor antigens: immunobiology and use in clinical trials. J. Immunol. 2007, 178, 1975-1979.
9. van der Bruggen, P.; Stroobant, V.; Vigneron, N.; Van den Eynde, B.J. Peptide database of T-cell defined tumor antigens. Cancer Immun. 2011, Updated in 11 January 2011, Available online at: http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm (accessed on 8 July 2011).
10. Speiser, D.E.; Lienard, D.; Rufer, N.; Rubio-Godoy, V.; Rimoldi, D.; Lejeune, F.; Krieg, A.M.; Cerottini, J.C.; Romero, P. Rapid and strong human CD8 T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005, 115, 739-746.
11. Rosenberg, S.A.; Yang, J.C.; Schwartzentruber, D.J.; Hwu, P.; Marincola, F.M.; Topalian, S.L.; Restifo, N.P.; Dudley, M.E.; Schwarz, S.L.; Spiess, P.J.; Wunderlich, J.P.; Parkhurst, M.R.; Kawakami, Y.; Seipp, C.A.; Einhorn, J.H.; White, D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 1998, 4, 321-327.
12. Marchand, M.; van Baren, N.; Weynants, P.; Brichard, V.; Dreno, B.; Tessier, M.-H.; Rankin, E.; Parmiani, G.; Arienti, F.; Humblet, Y.; Bourlond, A.; Vanwijck, R.; Lienard, D.; Beauduin, M.; Dietrich, P.-Y.; Russo, V.; Kerger, J.; Masucci, G.; Jager, E.; De Greve, J.; Atzpodien, J.; Brasseur, F.; Coulie, P.G.; van der Bruggen, P.; Boon, T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 1999, 80, 219-230.
13. Slingluff, C.L., Jr.; Petroni, G.R.; Yamshchikov, G.V.; Barnd, D.L.; Eastham, S.; Galavotti, H.; Patterson, J.W.; Deacon, D.H.; Hibbitts, S.; Teates, D.; Neese, P.Y.; Grosh, W.W.; Chianese-Bullock, K.A.; Woodson, E.M.; Wiernasz, C.J.; Merrill, P.; Gibson, J.; Ross, M.; Engelhard, V.H. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 2003, 21, 4016-4026.
14. Kruit, W.H.; van Ojik, H.H.; Brichard, V.G.; Escudier, B.; Dorval, T.; Dreno, B.; Patel, P.; van Baren, N.; Avril, M.-F.; Piperno, S.; Khammari, A.; Stas, M.; Ritter, G.; Lethe, B.; Godelaine, D.; Brasseur, F.; Zhang, Y.; van der Bruggen, P.; Boon, T.; Eggermont, A.M.; Marchand, M. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int. J. Cancer 2005, 117, 596-604.
15. van Baren, N.; Bonnet, M.-C.; Dreno, B.; Khammari, A.; Dorval, T.; Piperno-Neumann, S.; Lienard, D.; Speiser, D.; Marchand, M.; Brichard, V.G.; Escudier, B.; Negrier, S.; Dietrich, P.-Y.; Maraninchi, D.; Osanto, S.; Meyer, R.G.; Ritter, G.; Moingeon, P.; Tartaglia, J.; van der Bruggen, P.; Coulie, P.G.; Boon, T. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. 2005, 23, 9008-9021.
16. Thurner, B.; Haendle, I.; Roder, C.; Dieckmann, D.; Keikavoussi, P.; Jonuleit, H.; Bender, A.; Maczek, C.; Schreiner, D.; von den Driesch, P.; Brocker, E.B.; Steinman, R.M.; Enk, A.; Kampgen, E.; Schuler, G. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 1999, 190, 1669-1678.
17. + progenitor-derived dendritic cell vaccine. Cancer Res. 2001, 61, 6451-6458.
18. Boon, T.; Coulie, P.G.; Van den Eynde, B.; van der Bruggen, P. Human T cell responses against melanoma. Annu. Rev. Immunol. 2006, 24, 175-208.
19. Rosenberg, S.A.; Yang, J.C.; Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10, 909-915.
20. Wang, R.-F.; Appella, E.; Kawakami, Y.; Kang, X.; Rosenberg, S.A. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 1996, 184, 2207-2216.
21. Mahnke, Y.D.; Speiser, D.; Luescher, I.F.; Cerottini, J.-C.; Romero, P., Recent advances in tumour antigen-specific therapy: in vivo veritas. Int. J. Cancer 2005, 113, 173-178.
22. Coulie, P.G.; Karanikas, V.; Colau, D.; Lurquin, C.; Landry, C.; Marchand, M.; Dorval, T.; Brichard, V.; Boon, T. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. USA 2001, 98, 10290-10295.
23. Lonchay, C.; van der Bruggen, P.; Connerotte, T.; Hanagiri, T.; Coulie, P.; Colau, D.; Lucas, S.; Van Pel, A.; Thielemans, K.; van Baren, N.; Boon, T. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl. Acad. Sci. USA 2004, 101, 14631-14638.
24. de Vries, I.J.; Bernsen, M.R.; Lesterhuis, W.J.; Scharenborg, N.M.; Strijk, S.P.; Gerritsen, M.J.; Ruiter, D.J.; Figdor, C.G.; Punt, C.J.; Adema, G.J. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J. Clin. Oncol. 2005, 23, 5779-5787.
25. Terando, A.M.; Faries, M.B.; Morton, D.L. Vaccine therapy for melanoma: current status and future directions. Vaccine 2007, 25 (Suppl. 2), B4-16.
26. Lesterhuis, W.J.; Aarntzen, E.H.; De Vries, I.J.; Schuurhuis, D.H.; Figdor, C.G.; Adema, G.J.; Punt, C.J. Dendritic cell vaccines in melanoma: from promise to proof? Crit. Rev. Oncol. Hematol. 2008, 66, 118-134.
27. Larsen, T.E.; Grude, T.H. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I.3. The relation between the tumour-associated lymphocyte infiltration and age and sex, tumour cell type, pigmentation, cellular atypia, mitotic count, depth of invasion, ulceration, tumour type and prognosis. Acta Pathol. Microbiol. Scand. A 1978, 86A, 523-530.
28. Day, C.L.; Sober, A.J.; Kopf, A.W.; Lew, R.A.; Mihm, M.C.; Hennessey, P.; Golomb, F.M.; Harris, M.N.; Gumport, S.L.; Raker, J.W.; Malt, R.A.; Cosimi, A.B.; Wood, W.C.; Roses, D.F.; Gorstein, F.; Postel, A.; Grier, W.R.; Mintzis, M.N.; Fitzpatrick, T.B. A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann. Surg. 1981, 193, 436-440.
29. Johnson, O.K.; Emrich, L.J.; Karakousis, C.P.; Rao, U.; Greco, W.R. Comparison of prognostic factors for survival and recurrence in malignant melanoma of the skin, clinical Stage I. Cancer 1985, 55, 1107-1117.
30. Elder, D.E.; Guerry, D.; VanHorn, M.; Hurwitz, S.; Zehngebot, L.; Goldman, L.I.; LaRossa, D.; Hamilton, R.; Bondi, E.E.; Clark, W.H. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 1985, 56, 413-418.
31. Clark, W.H.; Elder, D.E.; Guerry, D.; Braitman, L.E.; Trock, B.J.; Schultz, D.; Synnestvedt, M.; Halpern, A.C. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 1989, 81, 1893-1904.
32. Pastorfide, G.C.; Kibbi, A.G.; de Roa, A.L.; Barnhill, R.L.; Sober, A.J.; Mihm, M.C.; Byers, H.R. Image analysis of stage 1 melanoma (1.00-2.50 mm): lymphocytic infiltrates related to metastasis and survival. J. Cutan. Pathol. 1992, 19, 390-397.
33. Barnhill, R.L.; Fine, J.A.; Roush, G.C.; Berwick, M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 1996, 78, 427-432.
34. Mihm, M.C., Jr.; Clemente, C.G.; Cascinelli, N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab. Invest. 1996, 74, 43-47.
35. Clemente, C.G.; Mihm, M.C., Jr.; Bufalino, R.; Zurrida, S.; Collini, P.; Cascinelli, N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77, 1303-1310.
36. Hernberg, M.; Turunen, J.P.; Muhonen, T.; Pyrhonen, S. Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy. J. Immunother. 1997, 20, 488-495.
37. Hakansson, A.; Gustafsson, B.; Krysander, L.; Hjelmqvist, B.; Rettrup, B.; Hakansson, L. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. Br. J. Cancer 2001, 85, 1871-1877.
38. Tuthill, R.J.; Unger, J.M.; Liu, P.Y.; Flaherty, L.E.; Sondak, V.K.; Group, S.O. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am. J. Clin. Pathol. 2002, 118, 504-511.
39. Ladanyi, A.; Somlai, B.; Gilde, K.; Fejos, Z.; Gaudi, I.; Timar, J. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin. Cancer Res. 2004, 10, 521-530.
40. Piras, F.; Colombari, R.; Minerba, L.; Murtas, D.; Floris, C.; Maxia, C.; Corbu, A.; Perra, M.T.; Sirigu, P. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005, 104, 1246-1254.
41. Haanen, J.B.; Baars, A.; Gomez, R.; Weder, P.; Smits, M.; de Gruijl, T.D.; von Blomberg, B.M.; Bloemena, E.; Scheper, R.J.; van Ham, S.M.; Pinedo, H.M.; van den Eertwegh, A.J. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol. Immunother. 2006, 55, 451-458.
42. Hussein, M.R.; Elsers, D.A.; Fadel, S.A.; Omar, A.E. Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions. J. Clin. Pathol. 2006, 59, 316-324.
43. Taylor, R.C.; Patel, A.; Panageas, K.S.; Busam, K.J.; Brady, M.S. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J. Clin. Oncol. 2007, 25, 869-875.
44. van Houdt, I.S.; Sluijter, B.J.; Moesbergen, L.M.; Vos, W.M.; de Gruijl, T.D.; Molenkamp, B.G.; van den Eertwegh, A.J.; Hooijberg, E.; van Leeuwen, P.A.; Meijer, C.J.; Oudejans, J.J. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int. J. Cancer 2008, 123, 609-615.
45. Mandala, M.; Imberti, G.L.; Piazzalunga, D.; Belfiglio, M.; Labianca, R.; Barberis, M.; Marchesi, L.; Poletti, P.; Bonomi, L.; Novellino, L.; Di Biagio, K.; Milesi, A.; Guerra, U.; Tondini, C. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Eur. J. Cancer 2009, 45, 2537-2545.
46. Bogunovic, D.; O'Neill, D.W.; Belitskaya-Levy, I.; Vacic, V.; Yu, Y.-L.; Adams, S.; Darvishian, F.; Berman, R.; Shapiro, R.; Pavlick, A.C.; Lonardi, S.; Zavadil, J.; Osman, I.; Bhardwaj, N. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc. Natl. Acad. Sci. USA 2009, 106, 20429-20434.
47. Rao, U.N.M.; Lee, S.J.; Luo, W.; Mihm, M.C.; Kirkwood, J.M. Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am. J. Clin. Pathol. 2010, 133, 646-653.
48. Morton, D.L.; Wen, D.R.; Wong, J.H.; Economou, J.S.; Cagle, L.A.; Storm, F.K.; Foshag, L.J.; Cochran, A.J. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 1992, 127, 392-399.
49. Kruper, L.L.; Spitz, F.R.; Czerniecki, B.J.; Fraker, D.L.; Blackwood-Chirchir, A.; Ming, M.E.; Elder, D.E.; Elenitsas, R.; Guerry, D.; Gimotty, P.A. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer 2006, 107, 2436-2445.
50. Naito, Y.; Saito, K.; Shiiba, K.; Ohuchi, A.; Saigenji, K.; Nagura, H.; Ohtani, H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998, 58, 3491-3494.
51. Prall, F.; Duhrkop, T.; Weirich, V.; Ostwald, C.; Lenz, P.; Nizze, H.; Barten, M. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum. Pathol. 2004, 35, 808-816.
52. Chiba, T.; Ohtani, H.; Mizoi, T.; Naito, Y.; Sato, E.; Nagura, H.; Ohuchi, A.; Ohuchi, K.; Shiiba, K.; Kurokawa, Y.; Satomi, S. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br. J. Cancer 2004, 91, 1711-1717.
53. Pages, F.; Berger, A.; Camus, M.; Sanchez-Cabo, F.; Costes, A.; Molidor, R.; Mlecnik, B.; Kirilovsky, A.; Nilsson, M.; Damotte, D.; Meatchi, T.; Bruneval, P.; Cugnenc, P.H.; Trajanoski, Z.; Fridman, W.H.; Galon, J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005, 353, 2654-2666.
54. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pages, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; Zinzindohoue, F.; Bruneval, P.; Cugnenc, P.H.; Trajanoski, Z.; Fridman, W.H.; Pages, F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960-1964.
55. Ohtani, H. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun. 2007, 7, 4.
56. Laghi, L.; Bianchi, P.; Miranda, E.; Balladore, E.; Pacetti, V.; Grizzi, F.; Allavena, P.; Torri, V.; Repici, A.; Santoro, A.; Mantovani, A.; Roncalli, M.; Malesci, A. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: A longitudinal study. Lancet Oncol. 2009, 10, 877-884.
57. Katz, S.C.; Pillarisetty, V.; Bamboat, Z.M.; Shia, J.; Hedvat, C.; Gonen, M.; Jarnagin, W.; Fong, Y.; Blumgart, L.; D'Angelica, M.; DeMatteo, R.P. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann. Surg. Oncol. 2009, 16, 2524-2530.
58. Mlecnik, B.; Tosolini, M.; Charoentong, P.; Kirilovsky, A.; Bindea, G.; Berger, A.; Camus, M.; Gillard, M.; Bruneval, P.; Fridman, W.-H.; Pages, F.; Trajanoski, Z.; Galon, J. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010, 138, 1429-1440.
59. Ropponen, K.M.; Eskelinen, M.J.; Lipponen, P.K.; Alhava, E.; Kosma, V.M. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J. Pathol. 1997, 182, 318-324.
60. Zhang, L.; Conejo-Garcia, J.R.; Katsaros, D.; Gimotty, P.A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H.; Schlienger, K.; Liebman, M.N.; Rubin, S.C.; Coukos, G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348, 203-213.
61. 3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol. Oncol. 2008, 108, 415-420.
62. Giuntoli, R.L., 2nd; Webb, T.J.; Zoso, A.; Rogers, O.; Diaz-Montes, T.P.; Bristow, R.E.; Oelke, M. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 2009, 29, 2875-2884.
63. Stumpf, M.; Hasenburg, A.; Riener, M.-O.; Jutting, U.; Wang, C.; Shen, Y.; Orlowska-Volk, M.; Fisch, P.; Wang, Z.; Gitsch, G.; Werner, M.; Lassmann, S. Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: Relevance of clonal selection of T lymphocytes. Br. J. Cancer 2009, 101, 1513-1521.
64. de Jong, R.A.; Leffers, N.; Boezen, H.M.; ten Hoor, K.A.; van der Zee, A.G.J.; Hollema, H.; Nijman, H.W. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol. Oncol. 2009, 114, 105-110.
65. Petersen, R.P.; Campa, M.J.; Sperlazza, J.; Conlon, D.; Joshi, M.-B.; Harpole, D.H.; Patz, E.F. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006, 107, 2866-2872.
66. Kilic, A.; Landreneau, R.J.; Luketich, J.D.; Pennathur, A.; Schuchert, M.J.; Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J. Surg. Res. 2011, 167, 207-210.
67. Ruffini, E.; Asioli, S.; Filosso, P.L.; Lyberis, P.; Bruna, M.C.; Macri, L.; Daniele, L.; Oliaro, A. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann. Thorac. Surg. 2009, 87, 365-371;discussion 371-372.
68. Xu, Y.; Kroft, S.H.; McKenna, R.W.; Aquino, D.B. Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study. Br. J. Haematol. 2001, 112, 945-949.
69. Dave, S.S.; Wright, G.; Tan, B.; Rosenwald, A.; Gascoyne, R.D.; Chan, W.C.; Fisher, R.I.; Braziel, R.M.; Rimsza, L.M.; Grogan, T.M.; Miller, T.P.; LeBlanc, M.; Greiner, T.C.; Weisenburger, D.D.; Lynch, J.C.; Vose, J.; Armitage, J.O.; Smeland, E.B.; Kvaloy, S.; Holte, H.; Delabie, J.; Connors, J.M.; Lansdorp, P.M.; Ouyang, Q.; Lister, T.A.; Davies, A.J.; Norton, A.J.; Muller-Hermelink, H.K.; Ott, G.; Campo, E.; Montserrat, E.; Wilson, W.H.; Jaffe, E.S.; Simon, R.; Yang, L.; Powell, J.; Zhao, H.; Goldschmidt, N.; Chiorazzi, M.; Staudt, L.M. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 2004, 351, 2159-2169.
70. Muris, J.J.F.; Meijer, C.J.L.M.; Cillessen, S.A.G.M.; Vos, W.; Kummer, J.A.; Bladergroen, B.A.; Bogman, M.J.J.T.; MacKenzie, M.A.; Jiwa, N.M.; Siegenbeek van Heukelom, L.H.; Ossenkoppele, G.J.; Oudejans, J.J. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 2004, 18, 589-596.
71. Schreck, S.; Friebel, D.; Buettner, M.; Distel, L.; Grabenbauer, G.; Young, L.S.; Niedobitek, G.; Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol. Oncol. 2009, 27, 31-39.
72. Lipponen, P.K.; Eskelinen, M.J.; Jauhiainen, K.; Harju, E.; Terho, R. Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur. J. Cancer 1992, 29A, 69-75.
73. Sharma, P.; Shen, Y.; Wen, S.; Yamada, S.; Jungbluth, A.A.; Gnjatic, S.; Bajorin, D.F.; Reuter, V.E.; Herr, H.; Old, L.J.; Sato, E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc. Natl. Acad. Sci. USA 2007, 104, 3967-3972.
74. Liakou, C.I.; Narayanan, S.; Ng Tang, D.; Logothetis, C.J.; Sharma, P. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun. 2007, 7, 10.
75. Yasunaga, M.; Tabira, Y.; Nakano, K.; Iida, S.; Ichimaru, N.; Nagamoto, N.; Sakaguchi, T. Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma. Ann. Thorac. Surg. 2000, 70, 1634-1640.
76. Schumacher, K.; Haensch, W.; Roefzaad, C.; Schlag, P.M. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001, 61, 3932-3936.
77. Gao, Q.; Qiu, S.-J.; Fan, J.; Zhou, J.; Wang, X.-Y.; Xiao, Y.-S.; Xu, Y.; Li, Y.-W.; Tang, Z.-Y.; Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 2007, 25, 2586-2593.
78. Chew, V.; Tow, C.; Teo, M.; Wong, H.L.; Chan, J.; Gehring, A.; Loh, M.; Bolze, A.; Quek, R.; Lee, V.K.M.; Lee, K.H.; Abastado, J.-P.; Toh, H.C.; Nardin, A. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J. Hepatol. 2010, 52, 370-379.
79. Brandwein-Gensler, M.; Teixeira, M.S.; Lewis, C.M.; Lee, B.; Rolnitzky, L.; Hille, J.J.; Genden, E.; Urken, M.L.; Wang, B.Y. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am. J. Surg. Pathol. 2005, 29, 167-178.
80. Badoual, C.; Hans, S.; Rodriguez, J.; Peyrard, S.; Klein, C.; Agueznay, N.E.H.; Mosseri, V.; Laccourreye, O.; Bruneval, P.; Fridman, W.H.; Brasnu, D.F.; Tartour, E.; Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 2006, 12, 465-472.
81. Watanabe, Y.; Katou, F.; Ohtani, H.; Nakayama, T.; Yoshie, O.; Hashimoto, K. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2010, 109, 744-752.
82. Uppaluri, R.; Dunn, G.P.; Lewis, J.S. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun. 2008, 8, 16.
83. Pretscher, D.; Distel, L.V.; Grabenbauer, G.G.; Wittlinger, M.; Buettner, M.; Niedobitek, G.; Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer 2009, 9, 292.
84. Zhang, Y.-L.; Li, J.; Mo, H.-Y.; Qiu, F.; Zheng, L.-M.; Qian, C.-N.; Zeng, Y.-X. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol. Cancer 2010, 9, 4.
85. Palma, L.; Di Lorenzo, N.; Guidetti, B. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. J. Neurosurg. 1978, 49, 854-861.
86. Brooks, W.H.; Markesbery, W.R.; Gupta, G.D.; Roszman, T.L.; Relationship of lymphocyte invasion and survival of brain tumor patients. Ann. Neurol. 1978, 4, 219-224.
87. Dunn, G.P.; Dunn, I.F.; Curry, W.T. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun. 2007, 7, 12.
88. Aaltomaa, S.; Lipponen, P.; Eskelinen, M.; Kosma, V.M.; Marin, S.; Alhava, E.; Syrjanen, K. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur. J. Cancer 1992, 28A, 859-864.
89. 8+ Lymphocytes Predict Clinical Outcome in Breast Cancer. J. Clin. Oncol. 2011, 29, 1949-1955.
90. Vesalainen, S.; Lipponen, P.; Talja, M.; Syrjanen, K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur. J. Cancer 1994, 30A, 1797-1803.
91. Grabenbauer, G.G.; Lahmer, G.; Distel, L.; Niedobitek, G. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin. Cancer Res. 2006, 12, 3355-3360.
92. Kolbeck, P.C.; Kaveggia, F.F.; Johansson, S.L.; Grune, M.T.; Taylor, R.J. The relationships among tumor-infiltrating lymphocytes, histopathologic findings, and long-term clinical follow-up in renal cell carcinoma. Mod. Pathol. 1992, 5, 420-425.
93. Nakano, O.; Sato, M.; Naito, Y.; Suzuki, K.; Orikasa, S.; Aizawa, M.; Suzuki, Y.; Shintaku, I.; Nagura, H.; Ohtani, H. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001, 61, 5132-5136.
94. Pollard, J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat.Rev. Cancer 2004, 4, 71-78.
95. Arstila, T.P.; Casrouge, A.; Baron, Y.; Even, J.; Kanellopoulos, J.; Kourilsky, P. A direct estimate of the human α β T cell receptor diversity. Science 1999, 286, 958-961.
96. Mackensen, A.; Carcelain, G.; Viel, S.; Raynal, M.C.; Michalaki, H.; Triebel, F.; Bosq, J.; Hercend, T. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J. Clin. Invest. 1994, 93, 1397-1402.
97. Puisieux, I.; Even, J.; Pannetier, C.; Jotereau, F.; Favrot, M.; Kourilsky, P. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J. Immunol. 1994, 153, 2807-2818.
98. Ferradini, L.; Mackensen, A.; Genevee, C.; Bosq, J.; Duvillard, P.; Avril, M.F.; Hercend, T. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J. Clin. Invest. 1993, 91, 1183-1190.
99. Strohal, R.; Paucz, L.; Pehamberger, H.; Stingl, G. T-cell receptor repertoire of lymphocytes infiltrating cutaneous melanoma is predominated by V alpha specificities present in T-cells of normal human skin. Cancer Res. 1994, 54, 4734-4739.
100. Clemente, C.; Rao, S.; Lupetti, R.; Tragni, G.; Pisarra, P.; Bersani, I.; Parmiani, G.; Mihm, M.C., Jr.; Sensi, M. Immunohistochemical analysis of the T-cell receptor beta-chain variable regions expressed by T lymphocytes infiltrating primary human melanoma. Lab. Invest. 1998, 78, 619-627.
101. Yazdi, A.S.; Morstedt, K.; Puchta, U.; Ghoreschi, K.; Flaig, M.J.; Rocken, M.; Sander, C.A. Heterogeneity of T-cell clones infiltrating primary malignant melanomas. J. Invest. Dermatol. 2006, 126, 393-398.
102. Thor Straten, P.; Becker, J.C.; Seremet, T.; Brocker, E.B.; Zeuthen, J.; Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J. Clin. Invest. 1996, 98, 279-284.
103. Echchakir, H.; Asselin-Paturel, C.; Dorothee, G.; Vergnon, I.; Grunenwald, D.; Chouaib, S.; Mami-Chouaib, F.; Analysis of T-cell-receptor beta-chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas. Int. J. Cancer 1999, 81, 205-213.
104. Weidmann, E.; Logan, T.F.; Yasumura, S.; Kirkwood, J.M.; Trucco, M.; Whiteside, T.L. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res. 1993, 53, 4745-4749.
105. Weidmann, E.; Whiteside, T.L.; Giorda, R.; Herberman, R.B.; Trucco, M. The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma. Cancer Res. 1992, 52, 5913-5920.
106. Ebato, M.; Nitta, T.; Yagita, H.; Sato, K.; Okumura, K. Skewed distribution of TCR V alpha 7-bearing T cells within tumor-infiltrating lymphocytes of HLA-A24(9)-positive patients with malignant glioma. Immunol. Lett. 1993, 39, 53-64.
107. Stephens, M.; Lim, K.; Stephens, P.; Thomas, D.W.; Lim, S.H. Molecular characterisation of tumour infiltrating lymphocytes in oral squamous cell carcinoma. Cancer Immunol. Immunother. 1998, 46, 34-40.
108. Zorn, E.; Hercend, T. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur. J. Immunol. 1999, 29, 602-607.
109. Zorn, E.; Hercend, T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur. J. Immunol. 1999, 29, 592-601.
110. Lurquin, C.; Lethe, B.; Corbiere, V.; Theate, I.; van Baren, N.; Coulie, P.G.; Boon, T.; Contrasting frequencies of anti-tumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. 2005, 201, 249-257.
111. Carrasco, J.; Van Pel, A.; Neyns, B.; Lethe, B.; Brasseur, F.; Renkvist, N.; van der Bruggen, P.; van Baren, N.; Paulus, R.; Thielemans, K.; Boon, T.; Godelaine, D. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J. Immunol. 2008, 180, 3585-3593.
112. Ma, W.; Germeau, C.; Vigneron, N.; Maernoudt, A.-S.; Morel, S.; Boon, T.; Coulie, P.G.; Van den Eynde, B.; Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int. J. Cancer 2004, 109, 698-702.
113. Pages, F.; Galon, J.; Dieu-Nosjean, M.C.; Tartour, E.; Sautes-Fridman, C.; Fridman, W.H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010, 29, 1093-1102.
114. Dieu-Nosjean, M.C.; Antoine, M.; Danel, C.; Heudes, D.; Wislez, M.; Poulot, V.; Rabbe, N.; Laurans, L.; Tartour, E.; de Chaisemartin, L.; Lebecque, S.; Fridman, W.H.; Cadranel, J. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 2008, 26, 4410-4417.
115. Grabowska, A.M.; Lechner, F.; Klenerman, P.; Tighe, P.J.; Ryder, S.; Ball, J.K.; Thomson, B.J.; Irving, W.L.; Robins, R.A. Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur. J. Immunol. 2001, 31, 2388-2394.
116. Anichini, A.; Molla, A.; Mortarini, R.; Tragni, G.; Bersani, I.; Di Nicola, M.; Gianni, A.M.; Pilotti, S.; Dunbar, R.; Cerundolo, V.; Parmiani, G. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J. Exp. Med. 1999, 190, 651-667.
117. Valmori, D.; Dutoit, V.; Lienard, D.; Lejeune, F.; Speiser, D.; Rimoldi, D.; Cerundolo, V.; Dietrich, P.-Y.; Cerottini, J.-C.; Romero, P. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. J. Immunol. 2000, 165, 533-538.
118. + T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000, 60, 4499-4506.
119. Corbiere, V.; Chapiro, J.; Stroobant, V.; Ma, W.; Lurquin, C.; Lethe, B.; van Baren, N.; Van den Eynde, B.J.; Boon, T.; Coulie, P.G. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 2011, 71, 1253-1262.
120. Germeau, C.; Ma, W.; Schiavetti, F.; Lurquin, C.; Henry, E.; Vigneron, N.; Brasseur, F.; Lethe, B.; De Plaen, E.; Velu, T.; Boon, T.; Coulie, P.G.; High frequency of anti-tumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 2005, 201, 241-248.
121. Vignard, V.; Lemercier, B.; Lim, A.; Pandolfino, M.C.; Guilloux, Y.; Khammari, A.; Rabu, C.; Echasserieau, K.; Lang, F.; Gougeon, M.L.; Dreno, B.; Jotereau, F.; Labarriere, N.; Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J. Immunol. 2005, 175, 4797-4805.
122. Santin, A.D.; Hermonat, P.L.; Ravaggi, A.; Bellone, S.; Roman, J.J.; Smith, C.V.; Pecorelli, S.; Radominska-Pandya, A.; Cannon, M.J.; Parham, G.P. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol. Obstet. Invest. 2001, 51, 254-561.
123. Gerdes, J.; Schwab, U.; Lemke, H.; Stein, H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer 1983, 31, 13-20.
124. Yakirevich, E.; Lefel, O.; Sova, Y.; Stein, A.; Cohen, O.; Izhak, O.B.; Resnick, M.B.; Activated status of tumour-infiltrating lymphocytes and apoptosis in testicular seminoma. J. Pathol. 2002, 196, 67-75.
125. Ashwell, S.; Zabludoff, S.; DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin. Cancer Res. 2008, 14, 4032-4037.
126. Weiss, E.M.; Frey, B.; Rodel, F.; Herrmann, M.; Schlucker, E.; Voll, R.E.; Fietkau, R.; Gaipl, U.S. Ex vivo- and in vivo-induced dead tumor cells as modulators of antitumor responses. Ann. N. Y. Acad. Sci. 2010, 1209, 109-117.
127. Barcia, C., Jr.; Gomez, A.; Gallego-Sanchez, J.M.; Perez-Valles, A.; Castro, M.G.; Lowenstein, P.R.; Barcia, C. Sr.; Herrero, M.T. Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells. Am. J. Pathol. 2009, 175, 786-798.
128. Andre, N.; Roquelaure, B.; Thuret, I.; Ziol, M.; Rieux-Laucat, F.; Le Deist, F. Expression of Granzyme B in viral hepatitis in patients with ALPS. Hepatology 2004, 39, 864-865.
129. Pham, B.N.; Martinot-Peignoux, M.; Valla, D.; Dubois, S.; Degott, C.; Mosnier, J.F. Differential expression of perforin and granzyme B in the liver of patients with chronic hepatitis C. Hum. Pathol. 2003, 34, 770-777.
130. Le Deist, F. Autoimmune lymphoproliferative syndrome. Orphanet 2005. Available online: http://www.orpha.net/ (accessed on 8 July 2011).
131. Wagner, P.; Koch, M.; Nummer, D.; Palm, S.; Galindo, L.; Autenrieth, D.; Rahbari, N.; Schmitz-Winnenthal, F.H.; Schirrmacher, V.; Buchler, M.W.; Beckhove, P.; Weitz, J.; Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann. Surg. Oncol. 2008, 15, 2310-2317.
132. Hadrup, S.R.; Braendstrup, O.; Jacobsen, G.K.; Mortensen, S.; Pedersen, L.O.; Seremet, T.; Andersen, M.H.; Becker, J.C.; Straten, P.T. Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells. Int. J. Cancer 2006, 119, 831-838.
133. Rubio, V.; Stuge, T.B.; Singh, N.; Betts, M.R.; Weber, J.S.; Roederer, M.; Lee, P.P.; Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 2003, 9, 1377-1382.
134. Ho, I.C.; Hodge, M.R.; Rooney, J.W.; Glimcher, L.H. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 1996, 85, 973-983.
135. Kim, J.I.; Ho, I.C.; Grusby, M.J.; Glimcher, L.H. The transcription factor c-Maf controls the production of interleukin-4 but not other Th2 cytokines. Immunity 1999, 10, 745-751.
136. De Monte, L.; Reni, M.; Tassi, E.; Clavenna, D.; Papa, I.; Recalde, H.; Braga, M.; Di Carlo, V.; Doglioni, C.; Protti, M.P.; Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp. Med. 2011, 208, 469-478.
137. Bazzoni, F.; Beutler, B.; The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 1996, 334, 1717-1725.
138. Boldrini, L.; Calcinai, A.; Samaritani, E.; Pistolesi, F.; Mussi, A.; Lucchi, M.; Angeletti, C.A.; Basolo, F.; Fontanini, G. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br. J. Cancer 2000, 83, 480-486.
139. Barth, R.J., Jr.; Camp, B.J.; Martuscello, T.A.; Dain, B.J.; Memoli, V.A. The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival. Cancer 1996, 78, 1168-1178.
140. Ubukata, H.; Konishi, S.; Nagata, H.; Kasuga, N.; Watanabe, Y.; Goto, Y.; Nakada, I.; Tabuchi, T.; Significance of preoperative evaluations of tumor necrosis factor-alpha, the granulocyte/lymphocyte ratio and their correlation with regard to outcome in gastric cancer patients. Dig. Surg. 2010, 27, 324-330.
141. Tisdale, M.J.; Biology of cachexia. J. Natl. Cancer Inst. 1997, 89, 1763-1773.
142. Warzocha, K.; Salles, G.; Bienvenu, J.; Barbier, Y.; Bastion, Y.; Doche, C.; Rieux, C.; Coiffier, B. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas. Leukemia 1997, 11 (Suppl. 3), 441-443.
143. Ferrajoli, A.; Keating, M.J.; Manshouri, T.; Giles, F.J.; Dey, A.; Estrov, Z.; Koller, C.A.; Kurzrock, R.; Thomas, D.A.; Faderl, S.; Lerner, S.; O'Brien, S.; Albitar, M. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002, 100, 1215-1219.
144. Hewala, T.I.; Abd El-Moneim, N.A.; Ebied, S.A.; Sheta, M.I.; Soliman, K.; Abu-Elenean, A. Diagnostic and prognostic value of serum nitric oxide, tumor necrosis factor-alpha, basic fibroblast growth factor and copper as angiogenic markers in premenopausal breast cancer patients: a case-control study. Br. J. Biomed. Sci. 2010, 67, 167-176.
145. Brailly, H.; Pebusque, M.J.; Tabilio, A.; Mannoni, P. TNF alpha acts in synergy with GM-CSF to induce proliferation of acute myeloid leukemia cells by up-regulating the GM-CSF receptor and GM-CSF gene expression. Leukemia 1993, 7, 1557-1563.
146. Wang, S.F.; Fouquet, S.; Chapon, M.; Salmon, H.; Regnier, F.; Labroquere, K.; Badoual, C.; Damotte, D.; Validire, P.; Maubec, E.; Delongchamps, N.B.; Cazes, A.; Gibault, L.; Garcette, M.; Dieu-Nosjean, M.C.; Zerbib, M.; Avril, M.F.; Prevost-Blondel, A.; Randriamampita, C.; Trautmann, A.; Bercovici, N. Early T cell signalling is reversibly altered in PD-1 T lymphocytes infiltrating human tumors. PLoS One 2011, 6, e17621.
147. Dudley, M.E.; Wunderlich, J.R.; Shelton, T.E.; Even, J.; Rosenberg, S.A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 2003, 26, 332-342.
148. Zippelius, A.; Batard, P.; Rubio-Godoy, V.; Bioley, G.; Lienard, D.; Lejeune, F.; Rimoldi, D.; Guillaume, P.; Meidenbauer, N.; Mackensen, A.; Rufer, N.; Lubenow, N.; Speiser, D.; Cerottini, J.-C.; Romero, P.; Pittet, M.J. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004, 64, 2865-2873.
149. Chen, Y.M.; Yang, W.K.; Whang-Peng, J.; Tsai, W.Y.; Hung, Y.M.; Yang, D.M.; Lin, W.C.; Perng, R.P.; Ting, C.C.; Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients. J. Immunother. 1997, 20, 354-364.
150. Ramsay, A.G.; Johnson, A.J.; Lee, A.M.; Gorgun, G.; Le Dieu, R.; Blum, W.; Byrd, J.C.; Gribben, J.G. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 2008, 118, 2427-2437.
151. Le Dieu, R.; Taussig, D.C.; Ramsay, A.G.; Mitter, R.; Miraki-Moud, F.; Fatah, R.; Lee, A.M.; Lister, T.A.; Gribben, J.G.; Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 2009, 114, 3909-3916.
152. Ramsay, A.G.; Clear, A.J.; Kelly, G.; Fatah, R.; Matthews, J.; Macdougall, F.; Lister, T.A.; Lee, A.M.; Calaminici, M.; Gribben, J.G. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009, 114, 4713-4720.
153. Harlin, H.; Kuna, T.V.; Peterson, A.C.; Meng, Y.; Gajewski, T.F. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol. Immunother. 2006, 55, 1185-1197.
154. Demotte, N.; Wieers, G.; Van Der Smissen, P.; Moser, M.; Schmidt, C.W.; Thielemans, K.; Squifflet, J.-L.; Weynand, B.; Carrasco, J.; Lurquin, C.; Courtoy, P.J.; van der Bruggen, P. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 2010, 70, 7476-7488.
155. Van den Hove, L.E.; Van Gool, S.W.; Van Poppel, H.; Baert, L.; Coorevits, L.; Van Damme, B.; Ceuppens, J.L.; Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clin. Exp. Immunol. 1997, 109,501-509.
156. Ye, S.W.; Wang, Y.; Valmori, D.; Ayyoub, M.; Han, Y.; Xu, X.L.; Zhao, A.L.; Qu, L.; Gnjatic, S.; Ritter, G.; Old, L.J.; Gu, J. Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content. J. Clin. Immunol. 2006, 26,447-456.
157. Marincola, F.; Jaffee, E.M.; Hicklin, D.J.; Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 2000, 74, 181-273.
158. Garrido, F.; Cabrera, T.; Aptsiauri, N.; Hard and soft lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int. J. Cancer 2010, 127, 249-256.
159. Anichini, A.; Mortarini, R.; Nonaka, D.; Molla, A.; Vegetti, C.; Montaldi, E.; Wang, X.; Ferrone, S. Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res. 2006, 66, 6405-6411.
160. Yokosuka, T.; Kobayashi, W.; Takamatsu, M.; Sakata-Sogawa, K.; Zeng, H.; Hashimoto-Tane, A.; Yagita, H.; Tokunaga, M.; Saito, T. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity 2010, 33, 326-339.
161. Vandenborre, K.; Van Gool, S.W.; Kasran, A.; Ceuppens, J.L.; Boogaerts, M.A.; Vandenberghe, P. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Immunology 1999, 98, 413-421.
162. Zou, W.; Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 2008, 8, 467-477.
163. Ahmadzadeh, M.; Johnson, L.A.; Heemskerk, B.; Wunderlich, J.R.; Dudley, M.E.; White, D.E.; Rosenberg, S.A. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114, 1537-1544.
164. Vandenborre, K.; Delabie, J.; Boogaerts, M.A.; De Vos, R.; Lorre, K.; De Wolf-Peeters, C.; Vandenberghe, P.; Human CTLA-4 is expressed in situ on T lymphocytes in germinal centers, in cutaneous graft-versus-host disease, and in Hodgkin's disease. Am. J. Pathol. 1998, 152, 963-973.
165. Melichar, B.; Nash, M.A.; Lenzi, R.; Platsoucas, C.D.; Freedman, R.S. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin. Exp. Immunol. 2000, 119, 19-27.
166. Hodi, F.S.; O'Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; Akerley, W.; van den Eertwegh, A.J.M.; Lutzky, J.; Lorigan, P.; Vaubel, J.M.; Linette, G.P.; Hogg, D.; Ottensmeier, C.H.; Lebbe, C.; Peschel, C.; Quirt, I.; Clark, J.I.; Wolchok, J.D.; Weber, J.S.; Tian, J.; Yellin, M.J.; Nichol, G.M.; Hoos, A.; Urba, W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711-723.
167. Kirkwood, J.M.; Lorigan, P.; Hersey, P.; Hauschild, A.; Robert, C.; McDermott, D.; Marshall, M.A.; Gomez-Navarro, J.; Liang, J.Q.; Bulanhagui, C.A.; Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin. Cancer Res. 2010, 16, 1042-1048.
168. Small, E.J.; Tchekmedyian, N.S.; Rini, B.I.; Fong, L.; Lowy, I.; Allison, J.P.; A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 2007, 13, 1810-1815.
169. O'Mahony, D.; Morris, J.C.; Quinn, C.; Gao, W.; Wilson, W.H.; Gause, B.; Pittaluga, S.; Neelapu, S.; Brown, M.; Fleisher, T.A.; Gulley, J.L.; Schlom, J.; Nussenblatt, R.; Albert, P.; Davis, T.A.; Lowy, I.; Petrus, M.; Waldmann, T.A.; Janik, J.E.; A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin. Cancer Res. 2007, 13, 958-964.
170. Royal, R.E.; Levy, C.; Turner, K.; Mathur, A.; Hughes, M.; Kammula, U.S.; Sherry, R.M.; Topalian, S.L.; Yang, J.C.; Lowy, I.; Rosenberg, S.A. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 2010, 33, 828-833.
171. Vonderheide, R.H.; LoRusso, P.M.; Khalil, M.; Gartner, E.M.; Khaira, D.; Soulieres, D.; Dorazio, P.; Trosko, J.A.; Ruter, J.; Mariani, G.L.; Usari, T.; Domchek, S.M.; Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res. 2010, 16, 3485-3494.
172. Chung, K.Y.; Gore, I.; Fong, L.; Venook, A.; Beck, S.B.; Dorazio, P.; Criscitiello, P.J.; Healey, D.I.; Huang, B.; Gomez-Navarro, J.; Saltz, L.B.; Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J. Clin. Oncol. 2010, 28, 3485-3490.
173. Phan, G.Q.; Yang, J.C.; Sherry, R.M.; Hwu, P.; Topalian, S.L.; Schwartzentruber, D.J.; Restifo, N.P.; Haworth, L.R.; Seipp, C.A.; Freezer, L.J.; Morton, K.E.; Mavroukakis, S.A.; Duray, P.H.; Steinberg, S.M.; Allison, J.P.; Davis, T.A.; Rosenberg, S.A.; Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 2003, 100, 8372-8377.
174. Hodi, F.S.; Butler, M.; Oble, D.A.; Seiden, M.V.; Haluska, F.G.; Kruse, A.; Macrae, S.; Nelson, M.; Canning, C.; Lowy, I.; Korman, A.; Lautz, D.; Russell, S.; Jaklitsch, M.T.; Ramaiya, N.; Chen, T.C.; Neuberg, D.; Allison, J.P.; Mihm, M.C.; Dranoff, G.; Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. USA 2008, 105, 3005-3010.
175. Camacho, L.H.; Antonia, S.; Sosman, J.; Kirkwood, J.M.; Gajewski, T.F.; Redman, B.; Pavlov, D.; Bulanhagui, C.; Bozon, V.A.; Gomez-Navarro, J.; Ribas, A. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 2009, 27, 1075-1081.
176. Wilgenhof, S.; Neyns, B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann. Oncol. 2011, 22, 991-993.
177. Callahan, M.K.; Wolchok, J.D.; Allison, J.P. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin. Oncol. 2010, 37, 473-484.
178. Chemnitz, J.M.; Parry, R.V.; Nichols, K.E.; June, C.H.; Riley, J.L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 2004, 173, 945-954.
179. Le Drean, E.; Vely, F.; Olcese, L.; Cambiaggi, A.; Guia, S.; Krystal, G.; Gervois, N.; Moretta, A.; Jotereau, F.; Vivier, E. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur. J. Immunol. 1998, 28, 264-276.
180. Shiroishi, M.; Tsumoto, K.; Amano, K.; Shirakihara, Y.; Colonna, M.; Braud, V.M.; Allan, D.S.; Makadzange, A.; Rowland-Jones, S.; Willcox, B.; Jones, E.Y.; van der Merwe, P.A.; Kumagai, I.; Maenaka, K. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc. Natl. Acad. Sci. USA 2003, 100, 8856-8861.
181. Perez-Villar, J.J.; Whitney, G.S.; Bowen, M.A.; Hewgill, D.H.; Aruffo, A.A.; Kanner, S.B. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol. Cell. Biol. 1999, 19, 2903-2912.
182. Fourmentraux-Neves, E.; Jalil, A.; Da Rocha, S.; Pichon, C.; Chouaib, S.; Bismuth, G.; Caignard, A. Two opposite signaling outputs are driven by the KIR2DL1 receptor in human CD4+ T cells. Blood 2008, 112, 2381-2389.
183. Lorenz, U. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol. Rev. 2009, 228, 342-359.
184. Wong, R.M.; Scotland, R.R.; Lau, R.L.; Wang, C.; Korman, A.J.; Kast, W.M.; Weber, J.S.; Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int. Immunol. 2007, 19, 1223-1234.
185. Dong, H.; Strome, S.E.; Salomao, D.R.; Tamura, H.; Hirano, F.; Flies, D.B.; Roche, P.C.; Lu, J.; Zhu, G.; Tamada, K.; Lennon, V.A.; Celis, E.; Chen, L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002, 8, 793-800.
186. Fourcade, J.; Kudela, P.; Sun, Z.; Shen, H.; Land, S.R.; Lenzner, D.; Guillaume, P.; Luescher, I.F.; Sander, C.; Ferrone, S.; Kirkwood, J.M.; Zarour, H.M. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J. Immunol. 2009, 182, 5240-5249.
187. Berger, R.; Rotem-Yehudar, R.; Slama, G.; Landes, S.; Kneller, A.; Leiba, M.; Koren-Michowitz, M.; Shimoni, A.; Nagler, A.; Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008, 14, 3044-3051.
188. Brahmer, J.R.; Drake, C.G.; Wollner, I.; Powderly, J.D.; Picus, J.; Sharfman, W.H.; Stankevich, E.; Pons, A.; Salay, T.M.; McMiller, T.L.; Gilson, M.M.; Wang, C.; Selby, M.; Taube, J.M.; Anders, R.; Chen, L.; Korman, A.J.; Pardoll, D.M.; Lowy, I.; Topalian, S.L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28, 3167-3175.
189. Fourcade, J.; Sun, Z.; Benallaoua, M.; Guillaume, P.; Luescher, I.F.; Sander, C.; Kirkwood, J.M.; Kuchroo, V.; Zarour, H.M.; Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 2010, 207, 2175-2186.
190. Nakamoto, N.; Cho, H.; Shaked, A.; Olthoff, K.; Valiga, M.E.; Kaminski, M.; Gostick, E.; Price, D.A.; Freeman, G.J.; Wherry, E.J.; Chang, K.M. Synergistic reversal of intrahepatic HCVspecific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 2009, 5,e1000313.
191. Derre, L.; Rivals, J.-P.; Jandus, C.; Pastor, S.; Rimoldi, D.; Romero, P.; Michielin, O.; Olive, D.; Speiser, D.E.; BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J. Clin. Invest. 2010, 120, 157-167.
192. Klibi, J.; Niki, T.; Riedel, A.; Pioche-Durieu, C.; Souquere, S.; Rubinstein, E.; Le Moulec, S.; Guigay, J.; Hirashima, M.; Guemira, F.; Adhikary, D.; Mautner, J.; Busson, P. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 2009, 113, 1957-1966.
193. Hirashima, M.; Kashio, Y.; Nishi, N.; Yamauchi, A.; Imaizumi, T.A.; Kageshita, T.; Saita, N.; Nakamura, T. Galectin-9 in physiological and pathological conditions. Glycoconj. J. 2004, 19,593-600.
194. Saverino, D.; Tenca, C.; Zarcone, D.; Merlo, A.; Megiovanni, A.M.; Valle, M.T.; Manca, F.; Grossi, C.E.; Ciccone, E. CTLA-4 (CD152) inhibits the specific lysis mediated by human cytolytic T lymphocytes in a clonally distributed fashion. J. Immunol. 1999, 162, 651-658.
195. Hodi, F.S.; Mihm, M.C.; Soiffer, R.J.; Haluska, F.G.; Butler, M.; Seiden, M.V.; Davis, T.; Henry-Spires, R.; MacRae, S.; Willman, A.; Padera, R.; Jaklitsch, M.T.; Shankar, S.; Chen, T.C.; Korman, A.; Allison, J.P.; Dranoff, G.; Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 2003, 100, 4712-4717.
196. Curiel, T.J.; Wei, S.; Dong, H.; Alvarez, X.; Cheng, P.; Mottram, P.; Krzysiek, R.; Knutson, K.L.; Daniel, B.; Zimmermann, M.C.; David, O.; Burow, M.; Gordon, A.; Dhurandhar, N.; Myers, L.; Berggren, R.; Hemminki, A.; Alvarez, R.D.; Emilie, D.; Curiel, D.T.; Chen, L.; Zou, W. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003, 9, 562-567.
197. Blank, C.; Kuball, J.; Voelkl, S.; Wiendl, H.; Becker, B.; Walter, B.; Majdic, O.; Gajewski, T.F.; Theobald, M.; Andreesen, R.; Mackensen, A. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int. J. Cancer 2006, 119, 317-327.
198. Selenko-Gebauer, N.; Majdic, O.; Szekeres, A.; Hofler, G.; Guthann, E.; Korthauer, U.; Zlabinger, G.; Steinberger, P.; Pickl, W.F.; Stockinger, H.; Knapp, W.; Stockl, J. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J. Immunol. 2003, 170, 3637-3644.
199. Bakker, A.B.; Phillips, J.H.; Figdor, C.G.; Lanier, L.L. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J. Immunol. 1998, 160, 5239-5245.
200. Mingari, M.C.; Moretta, A.; Moretta, L. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol. Today 1998, 19, 153-157.
201. Diermayr, S.; Himmelreich, H.; Durovic, B.; Mathys-Schneeberger, A.; Siegler, U.; Langenkamp, U.; Hofsteenge, J.; Gratwohl, A.; Tichelli, A.; Paluszewska, M.; Wiktor-Jedrzejczak, W.; Kalberer, C.P.; Wodnar-Filipowicz, A. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008, 111, 1428-1436.
202. Gray-Owen, S.D.; Blumberg, R.S. CEACAM1: contact-dependent control of immunity. Nat. Rev. Immunol. 2006, 6, 433-446.
203. Liu, W.; Guo, M.; Ezzat, S.; Asa, S.L. Vitamin D inhibits CEACAM1 to promote insulin/IGF-I receptor signaling without compromising anti-proliferative action. Lab. Invest. 2011, 91, 147-156.
204. Markel, G.; Seidman, R.; Stern, N.; Cohen-Sinai, T.; Izhaki, O.; Katz, G.; Besser, M.; Treves, J.; Blumberg, R.S.; Loewenthal, R.; Mandelboim, O.; Orenstein, A.; Schachter, J.; Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J. Immunol. 2006, 177, 6062-6071.
205. Sedy, J.R.; Gavrieli, M.; Potter, K.G.; Hurchla, M.A.; Lindsley, R.C.; Hildner, K.; Scheu, S.; Pfeffer, K.; Ware, C.F.; Murphy, T.L.; Murphy, K.M. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat. Immunol. 2005, 6, 90-98.
206. 4+ T cells through interaction with herpesvirus entry mediator. Nat. Immunol. 2008, 9, 176-185.
207. Golden-Mason, L.; Palmer, B.E.; Kassam, N.; Townshend-Bulson, L.; Livingston, S.; McMahon, J.; Castelblanco, N.; Kuchroo, V.; Gretch, D.R.; Rosen, H.R. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J. Virol. 2009, 83, 9122-9130.
208. Jones, R.B.; Ndhlovu, L.C.; Barbour, J.D.; Sheth, P.M.; Jha, A.R.; Long, B.R.; Wong, J.C.; Satkunarajah, M.; Schweneker, M.; Chapman, J.M.; Gyenes, G.; Vali, B.; Hyrcza, M.D.; Yue, F.Y.; Kovacs, C.; Sassi, A.; Loutfy, M.; Halpenny, R.; Persad, D.; Spotts, G.; Hecht, F.M.; Chun, T.W.; McCune, J.M.; Kaul, R.; Rini, J.M.; Nixon, D.F.; Ostrowski, M.A. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 2008, 205, 2763-2779.
209. McMahan, R.H.; Golden-Mason, L.; Nishimura, M.I.; McMahon, B.J.; Kemper, M.; Allen, T.M.; Gretch, D.R.; Rosen, H.R. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Invest. 2010, 120, 4546-4557.
210. Hastings, W.D.; Anderson, D.E.; Kassam, N.; Koguchi, K.; Greenfield, E.A.; Kent, S.C.; Zheng, X.X.; Strom, T.B.; Hafler, D.A.; Kuchroo, V.K. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur. J. Immunol. 2009, 39, 2492-2501.
211. Mingari, M.C.; Ponte, M.; Bertone, S.; Schiavetti, F.; Vitale, C.; Bellomo, R.; Moretta, A.; Moretta, L. HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells. Proc. Natl. Acad. Sci. USA 1998, 95, 1172-1177.
212. Speiser, D.E.; Pittet, M.J.; Valmori, D.; Dunbar, R.; Rimoldi, D.; Lienard, D.; MacDonald, H.R.; Cerottini, J.C.; Cerundolo, V.; Romero, P. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J. Exp. Med. 1999, 190, 775-782.
213. Sheu, B.C.; Chiou, S.H.; Lin, H.H.; Chow, S.N.; Huang, S.C.; Ho, H.N.; Hsu, S.M. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma. Cancer Res. 2005, 65, 2921-2929.
214. Saverino, D.; Merlo, A.; Bruno, S.; Pistoia, V.; Grossi, C.E.; Ciccone, E.; Dual effect of CD85/leukocyte Ig-like receptor-1/Ig-like transcript 2 and CD152 (CTLA-4) on cytokine production by antigen-stimulated human T cells. J. Immunol. 2002, 168, 207-215.
215. Ince, M.N.; Harnisch, B.; Xu, Z.; Lee, S.K.; Lange, C.; Moretta, L.; Lederman, M.; Lieberman, J. Increased expression of the natural killer cell inhibitory receptor CD85j/ILT2 on antigen-specific effector CD8 T cells and its impact on CD8 T-cell function. Immunology 2004, 112, 531-542.
216. Rosen, D.B.; Cao, W.; Avery, D.T.; Tangye, S.G.; Liu, Y.J.; Houchins, J.P.; Lanier, L.L. Functional consequences of interactions between human NKR-P1A and its ligand LLT1 expressed on activated dendritic cells and B cells. J. Immunol. 2008, 180, 6508-6517.
217. Brossard, C.; Semichon, M.; Trautmann, A.; Bismuth, G. CD5 inhibits signaling at the immunological synapse without impairing its formation. J. Immunol. 2003, 170, 4623-4629.
218. Dorothee, G.; Vergnon, I.; El Hage, F.; Le Maux Chansac, B.; Ferrand, V.; Lecluse, Y.; Opolon, P.; Chouaib, S.; Bismuth, G.; Mami-Chouaib, F. In situ sensory adaptation of tumor-infiltrating T lymphocytes to peptide-MHC levels elicits strong antitumor reactivity. J. Immunol. 2005, 174, 6888-6897.
219. + T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells. Cancer Res. 2009, 69, 4335-4345.
220. Stockis, J.; Fink, W.; Francois, V.; Connerotte, T.; De Smet, C.; Knoops, L.; van der Bruggen, P.; Boon, T.; Coulie, P.G.; Lucas, S.; Comparison of stable human Treg and Th clones by transcriptional profiling. Eur. J. Immunol. 2009, 39, 869-882.
221. Sakaguchi, S.; Miyara, M.; Costantino, C.M.; Hafler, D.A. FOXP3+regulatory T cells in the human immune system. Nat. Rev. Immunol. 2010, 10, 490-500.
222. Shevach, E.M. Mechanisms of FOXP3+T regulatory cell-mediated suppression. Immunity 2009, 30, 636-645.
223. Siddiqui, S.A.; Frigola, X.; Bonne-Annee, S.; Mercader, M.; Kuntz, S.M.; Krambeck, A.E.; Sengupta, S.; Dong, H.; Cheville, J.C.; Lohse, C.M.; Krco, C.J.; Webster, W.S.; Leibovich, B.C.; Blute, M.L.; Knutson, K.L.; Kwon, E.D. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin. Cancer Res. 2007, 13, 2075-2081.
224. Liotta, F.; Gacci, M.; Frosali, F.; Querci, V.; Vittori, G.; Lapini, A.; Santarlasci, V.; Serni, S.; Cosmi, L.; Maggi, L.; Angeli, R.; Mazzinghi, B.; Romagnani, P.; Maggi, E.; Carini, M.; Romagnani, S.; Annunziato, F. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int. 2011, 107, 1500-1506.
225. Shen, Z.; Zhou, S.; Wang, Y.; Li, R.-L.; Zhong, C.; Liang, C.; Sun, Y.; Higher intratumoral infiltrated FOXP3+Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J. Cancer Res. Clin. Oncol. 2010, 136, 1585-1595.
226. Curiel, T.J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J.R.; Zhang, L.; Burow, M.; Zhu, Y.; Wei, S.; Kryczek, I.; Daniel, B.; Gordon, A.; Myers, L.; Lackner, A.; Disis, M.L.; Knutson, K.L.; Chen, L.; Zou, W.; Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10, 942-949.
227. Bates, G.J.; Fox, S.B.; Han, C.; Leek, R.D.; Garcia, J.F.; Harris, A.L.; Banham, A.H.; Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 2006, 24, 5373-5380.
228. Mourmouras, V.; Fimiani, M.; Rubegni, P.; Epistolato, M.C.; Malagnino, V.; Cardone, C.; Cosci, E.; Nisi, M.C.D.; Miracco, C. Evaluation of tumour-infiltrating CD4+CD25+FOXP3+regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases. Br. J. Dermatol. 2007, 157, 531-539.
229. Miracco, C.; Mourmouras, V.; Biagioli, M.; Rubegni, P.; Mannucci, S.; Monciatti, I.; Cosci, E.; Tosi, P.; Luzi, P. Utility of tumour-infiltrating CD25+FOXP3+regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol. Rep. 2007, 18, 1115-1122.
230. Sato, E.; Olson, S.H.; Ahn, J.; Bundy, B.; Nishikawa, H.; Qian, F.; Jungbluth, A.A.; Frosina, D.; Gnjatic, S.; Ambrosone, C.; Kepner, J.; Odunsi, T.; Ritter, G.; Lele, S.; Chen, Y.T.; Ohtani, H.; Old, L.J.; Odunsi, K.; Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 18538-18543.
231. Griffiths, R.W.; Elkord, E.; Gilham, D.E.; Ramani, V.; Clarke, N.; Stern, P.L.; Hawkins, R.E.; Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol. Immunother. 2007, 56, 1743-1753.
232. Salama, P.; Phillips, M.; Grieu, F.; Morris, M.; Zeps, N.; Joseph, D.; Platell, C.; Iacopetta, B. Tumor-infiltrating FOXP3 T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 2009, 27, 186-192.
233. Lee, A.M.; Clear, A.J.; Calaminici, M.; Davies, A.J.; Jordan, S.; Macdougall, F.; Matthews, J.; Norton, A.J.; Gribben, J.G.; Lister, T.A.; Goff, L.K.; Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J. Clin. Oncol. 2006, 24, 5052-5059.
234. Haas, M.; Dimmler, A.; Hohenberger, W.; Grabenbauer, G.G.; Niedobitek, G.; Distel, L.V. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol. 2009, 9, 65.
235. Baron, U.; Floess, S.; Wieczorek, G.; Baumann, K.; Grutzkau, A.; Dong, J.; Thiel, A.; Boeld, T.J.; Hoffmann, P.; Edinger, M.; Turbachova, I.; Hamann, A.; Olek, S.; Huehn, J. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur. J. Immunol. 2007, 37, 2378-2389.
236. Dannull, J.; Su, Z.; Rizzieri, D.; Yang, B.K.; Coleman, D.; Yancey, D.; Zhang, A.; Dahm, P.; Chao, N.; Gilboa, E.; Vieweg, J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005, 115, 3623-3633.
237. Morse, M.A.; Hobeika, A.C.; Osada, T.; Serra, D.; Niedzwiecki, D.; Lyerly, H.K.; Clay, T.M. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008, 112, 610-618.
238. de Vries, I.J.M.; Castelli, C.; Huygens, C.; Jacobs, J.F.M.; Stockis, J.; Schuler-Thurner, B.; Adema, G.J.; Punt, C.J.A.; Rivoltini, L.; Schuler, G.; Coulie, P.G.; Lucas, S.; Frequency of circulating tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin. Cancer Res. 2011, 17, 841-848.
239. Thistlethwaite, F.C.; Elkord, E.; Griffiths, R.W.; Burt, D.J.; Shablak, A.M.; Campbell, J.D.; Gilham, D.E.; Austin, E.B.; Stern, P.L.; Hawkins, R.E. Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol. Immunother. 2008, 57, 623-634.
240. Audia, S.; Nicolas, A.; Cathelin, D.; Larmonier, N.; Ferrand, C.; Foucher, P.; Fanton, A.; Bergoin, E.; Maynadie, M.; Arnould, L.; Bateman, A.; Lorcerie, B.; Solary, E.; Chauffert, B.; Bonnotte, B.; Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin. Exp. Immunol. 2007, 150, 523-530.
241. Ghiringhelli, F.; Menard, C.; Puig, P.E.; Ladoire, S.; Roux, S.; Martin, F.; Solary, E.; Le Cesne, A.; Zitvogel, L.; Chauffert, B.; Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007, 56, 641-648.
242. Gattinoni, L.; Finkelstein, S.E.; Klebanoff, C.A.; Antony, P.A.; Palmer, D.C.; Spiess, P.J.; Hwang, L.N.; Yu, Z.; Wrzesinski, C.; Heimann, D.M.; Surh, C.D.; Rosenberg, S.A.; Restifo, N.P.; Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005, 202, 907-912.
243. Dudley, M.E.; Wunderlich, J.R.; Robbins, P.F.; Yang, J.C.; Hwu, P.; Schwartzentruber, D.J.; Topalian, S.L.; Sherry, R.; Restifo, N.P.; Hubicki, A.M.; Robinson, M.R.; Raffeld, M.; Duray, P.; Seipp, C.A.; Rogers-Freezer, L.; Morton, K.E.; Mavroukakis, S.A.; White, D.E.; Rosenberg, S.A.; Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298, 850-854.
244. Dudley, M.E.; Yang, J.C.; Sherry, R.; Hughes, M.S.; Royal, R.; Kammula, U.; Robbins, P.F.; Huang, J.; Citrin, D.E.; Leitman, S.F.; Wunderlich, J.; Restifo, N.P.; Thomasian, A.; Downey, S.G.; Smith, F.O.; Klapper, J.; Morton, K.; Laurencot, C.; White, D.E.; Rosenberg, S.A.; Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26, 5233-5239.
245. Jacobs, J.F.; Punt, C.J.; Lesterhuis, W.J.; Sutmuller, R.P.; Brouwer, H.M.; Scharenborg, N.M.; Klasen, I.S.; Hilbrands, L.B.; Figdor, C.G.; de Vries, I.J.; Adema, G.J.; Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 2010, 16, 5067-5078.
246. Makitie, T.; Summanen, P.; Tarkkanen, A.; Kivela, T.; Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2001, 42, 1414-1421.
247. Lissbrant, I.F.; Stattin, P.; Wikstrom, P.; Damber, J.E.; Egevad, L.; Bergh, A.; Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int. J. Oncol. 2000, 17, 445-451.
248. Hamada, I.; Kato, M.; Yamasaki, T.; Iwabuchi, K.; Watanabe, T.; Yamada, T.; Itoyama, S.; Ito, H.; Okada, K.; Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res. 2002, 22, 4281-4284.
249. Tsutsui, S.; Yasuda, K.; Suzuki, K.; Tahara, K.; Higashi, H.; Era, S.; Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol. Rep. 2005, 14, 425-431.
250. Ohno, S.; Ohno, Y.; Suzuki, N.; Kamei, T.; Koike, K.; Inagawa, H.; Kohchi, C.; Soma, G.; Inoue, M.; Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 2004, 24, 3335-3342.
251. Koide, N.; Nishio, A.; Sato, T.; Sugiyama, A.; Miyagawa, S.; Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am. J. Gastroenterol. 2004, 99, 1667-1674.
252. Leek, R.D.; Landers, R.J.; Harris, A.L.; Lewis, C.E.; Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer 1999, 79, 991-995.
253. Jadus, M.R.; Irwin, M.C.; Irwin, M.R.; Horansky, R.D.; Sekhon, S.; Pepper, K.A.; Kohn, D.B.; Wepsic, H.T.; Macrophages can recognize and kill tumor cells bearing the membrane isoform of macrophage colony-stimulating factor. Blood 1996, 87, 5232-5241.
254. Farinha, P.; Masoudi, H.; Skinnider, B.F.; Shumansky, K.; Spinelli, J.J.; Gill, K.; Klasa, R.; Voss, N.; Connors, J.M.; Gascoyne, R.D.; Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005, 106, 2169-2174.
255. Chong, H.; Vodovotz, Y.; Cox, G.W.; Barcellos-Hoff, M.H.; Immunocytochemical localization of latent transforming growth factor-beta1 activation by stimulated macrophages. J. Cell. Physiol. 1999, 178, 275-283.
256. Kryczek, I.; Zou, L.; Rodriguez, P.; Zhu, G.; Wei, S.; Mottram, P.; Brumlik, M.; Cheng, P.; Curiel, T.; Myers, L.; Lackner, A.; Alvarez, X.; Ochoa, A.; Chen, L.; Zou, W.; B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 2006, 203, 871-881.
257. Wink, D.A.; Vodovotz, Y.; Laval, J.; Laval, F.; Dewhirst, M.W.; Mitchell, J.B.; The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998, 19, 711-721.
258. Massi, D.; Marconi, C.; Franchi, A.; Bianchini, F.; Paglierani, M.; Ketabchi, S.; Miracco, C.; Santucci, M.; Calorini, L.; Arginine metabolism in tumor-associated macrophages in cutaneous malignant melanoma: Evidence from human and experimental tumors. Hum. Pathol. 2007, 38, 1516-1525.
259. MacMicking, J.; Xie, Q.W.; Nathan, C.; Nitric oxide and macrophage function. Annu. Rev. Immunol. 1997, 15, 323-350.
260. Mrena, J.; Wiksten, J.P.; Thiel, A.; Kokkola, A.; Pohjola, L.; Lundin, J.; Nordling, S.; Ristimaki, A.; Haglund, C.; Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin. Cancer Res. 2005, 11, 7362-7368.
261. Gasparini, G.; Longo, R.; Sarmiento, R.; Morabito, A.; Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol. 2003, 4, 605-615.
262. Denkert, C.; Winzer, K.J.; Hauptmann, S.; Prognostic impact of cyclooxygenase-2 in breast cancer. Clin. Breast Cancer 2004, 4, 428-433.
263. Hasler, F.; Bluestein, H.G.; Zvaifler, N.J.; Epstein, L.B.; Analysis of the defects responsible for the impaired regulation of EBV-induced B cell proliferation by rheumatoid arthritis lymphocytes. II. Role of monocytes and the increased sensitivity of rheumatoid arthritis lymphocytes to prostaglandin E. J. Immunol. 1983, 131, 768-772.
264. Goodwin, J.S.; Ceuppens, J.; Regulation of the immune response by prostaglandins. J. Clin. Immunol. 1983, 3, 295-315.
265. Betz, M.; Fox, B.S.; Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J. Immunol. 1991, 146, 108-113.
266. Rodriguez, P.C.; Hernandez, C.P.; Quiceno, D.; Dubinett, S.M.; Zabaleta, J.; Ochoa, J.B.; Gilbert, J.; Ochoa, A.C.; Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 2005, 202, 931-939.
267. Serafini, P.; Meckel, K.; Kelso, M.; Noonan, K.; Califano, J.; Koch, W.; Dolcetti, L.; Bronte, V.; Borrello, I.; Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 2006, 203, 2691-2702.
268. Ohno, S.; Inagawa, H.; Dhar, D.K.; Fujii, T.; Ueda, S.; Tachibana, M.; Suzuki, N.; Inoue, M.; Soma, G.; Nagasue, N.; The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res. 2003, 23, 5015-5022.
269. Funada, Y.; Noguchi, T.; Kikuchi, R.; Takeno, S.; Uchida, Y.; Gabbert, H.E.; Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol. Rep. 2003, 10, 309-313.
270. Letterio, J.J.; Roberts, A.B.; Regulation of immune responses by TGF-beta. Annu. Rev. Immunol. 1998, 16, 137-161.
271. Blobe, G.C.; Schiemann, W.P.; Lodish, H.F.; Role of transforming growth factor beta in human disease. N. Engl. J. Med. 2000, 342, 1350-1358.
272. Li, M.O.; Wan, Y.Y.; Sanjabi, S.; Robertson, A.K.; Flavell, R.A.; Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 2006, 24, 99-146.
273. Taga, K.; Mostowski, H.; Tosato, G.; Human interleukin-10 can directly inhibit T-cell growth. Blood 1993, 81, 2964-2971.
274. Schandene, L.; Alonso-Vega, C.; Willems, F.; Gerard, C.; Delvaux, A.; Velu, T.; Devos, R.; de Boer, M.; Goldman, M.; B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J. Immunol. 1994, 152, 4368-4374.
275. Trachtman, H.; Fervenza, F.C.; Gipson, D.S.; Heering, P.; Jayne, D.R.; Peters, H.; Rota, S.; Remuzzi, G.; Rump, L.C.; Sellin, L.K.; Heaton, J.P.; Streisand, J.B.; Hard, M.L.; Ledbetter, S.R.; Vincenti, F.; A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 2011, 79, 1236-1243.
276. Klyosov, A.A.; Zomer, E.; Platt, D.; DAVANAT® and colon cancer: Preclinical and clinical (phase I) studies. A.C.S. Symposium Series 2006, 932, 67-104.
277. Miller, M.C.; Klyosov, A.; Mayo, K.H.; The alpha-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain. Glycobiology 2009, 79, 1034-1045.
278. Chemnitz, J.M.; Driesen, J.; Classen, S.; Riley, J.L.; Debey, S.; Beyer, M.; Popov, A.; Zander, T.; Schultze, J.L.; Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res. 2006, 66, 1114-1122.
279. von Bergwelt-Baildon, M.S.; Popov, A.; Saric, T.; Chemnitz, J.; Classen, S.; Stoffel, M.S.; Fiore, F.; Roth, U.; Beyer, M.; Debey, S.; Wickenhauser, C.; Hanisch, F.G.; Schultze, J.L.; CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 2006, 708, 228-237.
280. Lonnroth, C.; Andersson, M.; Arvidsson, A.; Nordgren, S.; Brevinge, H.; Lagerstedt, K.; Lundholm, K.; Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun. 2008, 8, 5.
281. Cross, D.S.; Platt, J.L.; Juhn, S.K.; Bach, F.H.; Adams, G.L.; Tumor infiltrating lymphocytes in squamous cell carcinoma of the head and neck: Mechanisms of enhancement using prostaglandin synthetase inhibitors. Adv. Exp. Med. Biol. 1997, 400B, 1013-1024.
282. Bronte, V.; Kasic, T.; Gri, G.; Gallana, K.; Borsellino, G.; Marigo, I.; Battistini, L.; Iafrate, M.; Prayer-Galetti, T.; Pagano, F.; Viola, A.; Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 2005, 207, 1257-1268.
283. Brito, C.; Naviliat, M.; Tiscornia, A.C.; Vuillier, F.; Gualco, G.; Dighiero, G.; Radi, R.; Cayota, A.M.; Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J. Immunol. 1999, 762, 3356-3366.
284. Rodriguez, P.C.; Zea, A.H.; Culotta, K.S.; Zabaleta, J.; Ochoa, J.B.; Ochoa, A.C.; Regulation of T cell receptor CD3zeta chain expression by L-arginine. J. Biol. Chem. 2002, 277, 21123-21129.
285. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B.J.; Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9, 1269-1274.
286. Di Pucchio, T.; Danese, S.; De Cristofaro, R.; Rutella, S.; Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds. Expert Opin. Ther. Pat. 2010, 20, 229-250.
287. Qian, F.; Villella, J.; Wallace, P.K.; Mhawech-Fauceglia, P.; Tario, J.D.; Andrews, C.; Matsuzaki, J.; Valmori, D.; Ayyoub, M.; Frederick, P.J.; Beck, A.; Liao, J.; Cheney, R.; Moysich, K.; Lele, S.; Shrikant, P.; Old, L.J.; Odunsi, K.; Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res. 2009, 69, 5498-5504.
288. Yue, E.W.; Douty, B.; Wayland, B.; Bower, M.; Liu, X.; Leffet, L.; Wang, Q.; Bowman, K.J.; Hansbury, M.J.; Liu, C.; Wei, M.; Li, Y.; Wynn, R.; Burn, T.C.; Koblish, H.K.; Fridman, J.S.; Metcalf, B.; Scherle, P.A.; Combs, A.P.; Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J. Med. Chem. 2009, 52, 7364-7367.
289. Rohrig, U.F.; Awad, L.; Grosdidier, A.; Larrieu, P.; Stroobant, V.; Colau, D.; Cerundolo, V.; Simpson, A.J. G.; Vogel, P.; Van den Eynde, B.J.; Zoete, V.; Michielin, O.; Rational design of indoleamine 2,3-dioxygenase inhibitors. J. Med. Chem. 2010, 53, 1172-1189.
290. de Waal Malefyt, R.; Haanen, J.; Spits, H.; Roncarolo, M.G.; te Velde, A.; Figdor, C.; Johnson, K.; Kastelein, R.; Yssel, H.; de Vries, J.E.; Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 1991, 174, 915-924.
291. de Waal Malefyt, R.; Yssel, H.; de Vries, J.E.; Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J. Immunol. 1993, 150, 4754-4765.
292. Terai, M.; Tamura, Y.; Alexeev, V.; Ohtsuka, E.; Berd, D.; Mastrangelo, M.J.; Sato, T.; Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol. Immunother. 2009, 58, 1307-1317.
293. Chhabra, A.; Chakraborty, N.G.; Mukherji, B.; Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35. Clin. Immunol. 2008, 126, 251-259.
294. Llorente, L.; Richaud-Patin, Y.; Garcia-Padilla, C.; Claret, E.; Jakez-Ocampo, J.; Cardiel, M.H.; Alcocer-Varela, J.; Grangeot-Keros, L.; Alarcon-Segovia, D.; Wijdenes, J.; Galanaud, P.; Emilie, D.; Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000, 43, 1790-1800.
295. Raskovalova, T.; Lokshin, A.; Huang, X.; Su, Y.; Mandic, M.; Zarour, H.M.; Jackson, E.K.; Gorelik, E.; Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res. 2007, 67, 5949-5956.
296. Hilchey, S.P.; Kobie, J.J.; Cochran, M.R.; Secor-Socha, S.; Wang, J.C.; Hyrien, O.; Burack, W.R.; Mosmann, T.R.; Quataert, S.A.; Bernstein, S.H.; Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness. J. Immunol. 2009, 183, 6157-6166.
297. Biaggioni, I.; Paul, S.; Puckett, A.; Arzubiaga, C.; Caffeine and theophylline as adenosine receptor antagonists in humans. J. Pharmacol. Exp. Ther. 1991, 258, 588-593.
298. Zhu, C.; Anderson, A.C.; Schubart, A.; Xiong, H.; Imitola, J.; Khoury, S.J.; Zheng, X.X.; Strom, T.B.; Kuchroo, V.K.; The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005, 6, 1245-1252.
299. Terness, P.; Bauer, T.M.; Rose, L.; Dufter, C.; Watzlik, A.; Simon, H.; Opelz, G.; Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 2002, 196, 447-457.
300. Weber, W.P.; Feder-Mengus, C.; Chiarugi, A.; Rosenthal, R.; Reschner, A.; Schumacher, R.; Zajac, P.; Misteli, H.; Frey, D.M.; Oertli, D.; Heberer, M.; Spagnoli, G.C.; Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines. Eur. J. Immunol. 2006, 36, 296-304.
301. Grohmann, U.; Fallarino, F.; Puccetti, P.; Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 2003, 24, 242-248.
302. Fallarino, F.; Grohmann, U.; Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T cell functions. Curr. Med. Chem. 2011, 18, 2215-2221.
303. Chung, D.J.; Rossi, M.; Romano, E.; Ghith, J.; Yuan, J.; Munn, D.H.; Young, J.W.; Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009, 114, 555-563.
304. Brody, J.R.; Costantino, C.L.; Berger, A.C.; Sato, T.; Lisanti, M.P.; Yeo, C.J.; Emmons, R.V.; Witkiewicz, A.K.; Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 2009, 8, 1930-1934.
305. Inaba, T.; Ino, K.; Kajiyama, H.; Yamamoto, E.; Shibata, K.; Nawa, A.; Nagasaka, T.; Akimoto, H.; Takikawa, O.; Kikkawa, F.; Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol. Oncol. 2009, 115, 185-192.
306. Gao, Y.F.; Peng, R.Q.; Li, J.; Ding, Y.; Zhang, X.; Wu, X.J.; Pan, Z.Z.; Wan, D.S.; Zeng, Y.X.; Zhang, X.S.; The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J. Transl. Med. 2009, 7, 71.
307. Nelson, B.H.; IDO and outcomes in ovarian cancer. Gynecol. Oncol. 2009, 115, 179-180.
308. Pan, K.; Wang, H.; Chen, M.S.; Zhang, H.K.; Weng, D.S.; Zhou, J.; Huang, W.; Li, J.J.; Song, H.F.; Xia, J.C.; Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2008, 134, 1247-1253.
309. Jacquemier, J.; Bertucci, F.; Finetti, P.; Esterni, B.; Charafe-Jauffret, E.; Thibult, M.L.; Houvenaeghel, G.; Van den Eynde, B.; Birnbaum, D.; Olive, D.; Xerri, L.; High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int. J. Cancer 2011, advance epub, Feb. 15.
310. Bronte, V.; Zanovello, P.; Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 2005, 5, 641-654.
311. Singer, K.; Gottfried, E.; Kreutz, M.; Mackensen, A.; Suppression of T-cell responses by tumor metabolites. Cancer Immunol. Immunother. 2011, 60, 425-431.
312. Fischer, K.; Hoffmann, P.; Voelkl, S.; Meidenbauer, N.; Ammer, J.; Edinger, M.; Gottfried, E.; Schwarz, S.; Rothe, G.; Hoves, S.; Renner, K.; Timischl, B.; Mackensen, A.; Kunz-Schughart, L.; Andreesen, R.; Krause, S.W.; Kreutz, M.; Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007, 709, 3812-3819.
313. Feder-Mengus, C.; Ghosh, S.; Weber, W.P.; Wyler, S.; Zajac, P.; Terracciano, L.; Oertli, D.; Heberer, M.; Martin, I.; Spagnoli, G.C.; Reschner, A.; Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes. Br. J. Cancer 2007, 96, 1072-1082.
314. Sitkovsky, M.V.; Kjaergaard, J.; Lukashev, D.; Ohta, A.; Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin. Cancer Res. 2008, 74, 5947-5952.
315. Deaglio, S.; Dwyer, K.M.; Gao, W.; Friedman, D.; Usheva, A.; Erat, A.; Chen, J.F.; Enjyoji, K.; Linden, J.; Oukka, M.; Kuchroo, V.K.; Strom, T.B.; Robson, S.C.; Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007, 204, 1257-1265.
316. Mandapathil, M.; Hilldorfer, B.; Szczepanski, M.J.; Czystowska, M.; Szajnik, M.; Ren, J.; Lang, S.; Jackson, E.K.; Gorelik, E.; Whiteside, T.L.; Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J. Biol. Chem. 2010, 285, 7176-7186.
317. Blay, J.; White, T.D.; Hoskin, D.W.; The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 1997, 57, 2602-2605.
318. Ambs, S.; Merriam, W.G.; Bennett, W.P.; Felley-Bosco, E.; Ogunfusika, M.O.; Oser, S.M.; Klein, S.; Shields, P.G.; Billiar, T.R.; Harris, C.C.; Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 1998, 58, 334-341.
319. + T cell tolerance in cancer. Nat. Med. 2007, 73, 828-835.
320. Brandau, S.; Trellakis, S.; Bruderek, K.; Schmaltz, D.; Steller, G.; Elian, M.; Suttmann, H.; Schenck, M.; Welling, J.; Zabel, P.; Lang, S.; Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J. Leukoc. Biol. 2011, 89, 311-317.
321. Rodriguez, P.C.; Ernstoff, M.S.; Hernandez, C.; Atkins, M.; Zabaleta, J.; Sierra, R.; Ochoa, A.C.; Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009, 69, 1553-1560.
322. Kasic, T.; Colombo, P.; Soldani, C.; Wang, C.M.; Miranda, E.; Roncalli, M.; Bronte, V.; Viola, A.; Modulation of human T cell functions by reactive nitrogen species. Eur. J. Immunol. 2011, in press.
323. Demotte, N.; Stroobant, V.; Courtoy, P.J.; Van Der Smissen, P.; Colau, D.; Luescher, I.F.; Hivroz, C.; Nicaise, J.; Squifflet, J.L.; Mourad, M.; Godelaine, D.; Boon, T.; van der Bruggen, P.; Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 2008, 28, 414-424.
324. Rabinovich, G.A.; Toscano, M.A.; Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol. 2009, 9, 338-352.
325. Cummings, R.D.; Liu, F.-T.; Galectins. In Essentials of Glycobiology, second ed.; Varki, A.; Cummings, R.D.; Esko, J.D.; Freeze, H.H.; Stanley, P.; Bertozzi, C.R.; Hart, G.W.; Etzler, M.E. Eds. Cold Spring Harbor Laboratory Press: New York, NY, USA, 2009.
326. Yu, F.; Finley, R.L., Jr.; Raz, A.; Kim, H.R.; Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J. Biol. Chem. 2002, 277, 15819-15827.
327. Wang, J.L.; Gray, R.M.; Haudek, K.C.; Patterson, R.J.; Nucleocytoplasmic lectins. Biochim. Biophys. Acta 2004, 1673, 75-93.
328. Lau, K.S.; Partridge, E.A.; Grigorian, A.; Silvescu, C.I.; Reinhold, V.N.; Demetriou, M.; Dennis, J.W.; Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 2007, 129, 123-134.
329. Pace, K.E.; Lee, C.; Stewart, P.L.; Baum, L.G.; Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J. Immunol. 1999, 163, 3801-3811.
330. Hughes, R.C.; Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim. Biophys. Acta 1999, 1473, 172-185.
331. van den Brule, F.; Califice, S.; Castronovo, V.; Expression of galectins in cancer: a critical review. Glycoconj. J. 2004, 19, 537-542.
332. Demydenko, D.; Berest, I.; Expression of galectin-1 in malignant tumors. Exp. Oncol. 2009, 31, 74-79.
333. Greco, C.; Vona, R.; Cosimelli, M.; Matarrese, P.; Straface, E.; Scordati, P.; Giannarelli, D.; Casale, V.; Assisi, D.; Mottolese, M.; Moles, A.; Malorni, W.; Cell surface overexpression of galectin-3 and the presence of its ligand 90k in the blood plasma as determinants in colon neoplastic lesions. Glycobiology 2004, 14, 783-792.
334. Liu, F.T.; Hsu, D.K.; Zuberi, R.I.; Kuwabara, I.; Chi, E.Y.; Henderson, W.R., Jr.; Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am. J. Pathol. 1995, 147, 1016-1028.
335. Hsu, D.K.; Chen, H.Y.; Liu, F.T.; Galectin-3 regulates T-cell functions. Immunol. Rev. 2009, 230, 114-127.
336. Garin, M.I.; Chu, C.-C.; Golshayan, D.; Cernuda-Morollon, E.; Wait, R.; Lechler, R.I. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 2007, 109, 2058-2065.
337. Sioud, M.; Mobergslien, A.; Boudabous, A.; Floisand, Y.; Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int. J. Oncol. 2011, 38, 385-390.
338. Sioud, M.; Mobergslien, A.; Boudabous, A.; Floisand, Y.; Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand. J. Immunol. 2010, 71, 267-274.
339. Sioud, M. New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand. J. Immunol. 2011, 73, 79-84.
340. Najar, M.; Raicevic, G.; Id Boufker, H.; Stamatopoulos, B.; De Bruyn, C.; Meuleman, N.; Bron, D.; Toungouz, M.; Lagneaux, L.; Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions. Exp. Hematol. 2010, 38, 922-932.
341. Vereecken, P.; Debray, C.; Petein, M.; Awada, A.; Lalmand, M.C.; Laporte, M.; Van Den Heule, B.; Verhest, A.; Pochet, R.; Heenen, M.; Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors. Arch. Dermatol. Res. 2005, 296, 353-358.
342. Iurisci, I.; Tinari, N.; Natoli, C.; Angelucci, D.; Cianchetti, E.; Iacobelli, S.; Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin. Cancer Res. 2000, 6, 1389-1393.
343. Vereecken, P.; Awada, A.; Suciu, S.; Castro, G.; Morandini, R.; Litynska, A.; Lienard, D.; Ezzedine, K.; Ghanem, G.; Heenen, M.; Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res. 2009, 79, 316-320.
344. Vereecken, P.; Ghanem, G.; Morandini, R.; Suciu, S.; Van Baren, N.; Heenen, M.; Defining the prognostic value for galectin-3 in cutaneous melanoma. J. Int. Med. Res. 2007, 35, 731-732.
345. Saussez, S.; Lorfevre, F.; Lequeux, T.; Laurent, G.; Chantrain, G.; Vertongen, F.; Toubeau, G.; Decaestecker, C.; Kiss, R.; The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral. Oncol. 2008, 44, 86-93.
346. Perillo, N.L.; Pace, K.E.; Seilhamer, J.J.; Baum, L.G.; Apoptosis of T cells mediated by galectin-1. Nature 1995, 378, 736-739.
347. Bi, S.; Earl, L.A.; Jacobs, L.; Baum, L.G.; Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. J. Biol. Chem. 2008, 283, 12248-12258.
348. Kashio, Y.; Nakamura, K.; Abedin, M.J.; Seki, M.; Nishi, N.; Yoshida, N.; Nakamura, T.; Hirashima, M.; Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J. Immunol. 2003, 770, 3631-3636.
349. Fukumori, T.; Takenaka, Y.; Yoshii, T.; Kim, H.R.; Hogan, V.; Inohara, H.; Kagawa, S.; Raz, A.; CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res. 2003, 63, 8302-8311.
350. van der Leij, J.; van den Berg, A.; Harms, G.; Eschbach, H.; Vos, H.; Zwiers, P.; van Weeghel, R.; Groen, H.; Poppema, S.; Visser, L.; Strongly enhanced IL-10 production using stable galectin-1 homodimers. Mol. Immunol. 2007, 44, 506-513.
351. Juszczynski, P.; Ouyang, J.; Monti, S.; Rodig, S.J.; Takeyama, K.; Abramson, J.; Chen, W.; Kutok, J.L.; Rabinovich, G.A.; Shipp, M.A.; The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. USA 2007, 704, 13134-13139.
352. Gandhi, M.K.; Moll, G.; Smith, C.; Dua, U.; Lambley, E.; Ramuz, O.; Gill, D.; Marlton, P.; Seymour, J.F.; Khanna, R.; Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 2007, 770, 1326-1329.
353. Perillo, N.L.; Uittenbogaart, C.H.; Nguyen, J.T.; Baum, L.G.; Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J. Exp. Med. 1997, 785, 1851-1858.
354. Valenzuela, H.F.; Pace, K.E.; Cabrera, P.V.; White, R.; Porvari, K.; Kaija, H.; Vihko, P.; Baum, L.G.; O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1. Cancer Res. 2007, 67, 6155-6162.
355. Suzuki, O.; Abe, M.; Cell surface N-glycosylation and sialylation regulate galectin-3-induced apoptosis in human diffuse large B cell lymphoma. Oncol. Rep. 2008, 19, 743-748.
356. Kageshita, T.; Kashio, Y.; Yamauchi, A.; Seki, M.; Abedin, M.J.; Nishi, N.; Shoji, H.; Nakamura, T.; Ono, T.; Hirashima, M.; Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int. J. Cancer 2002, 99, 809-816.
357. He, J.; Baum, L.G.; Presentation of galectin-1 by extracellular matrix triggers T cell death. J. Biol. Chem. 2004, 279, 4705-4712.
358. Walzel, H.; Blach, M.; Hirabayashi, J.; Kasai, K.I.; Brock, J.; Involvement of CD2 and CD3 in galectin-1 induced signaling in human Jurkat T-cells. Glycobiology 2000, 10, 131-140.
359. Earl, L.A.; Bi, S.; Baum, L.G.; N- and O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death. J. Biol. Chem. 2010, 285, 2232-2244.
360. Stillman, B.N.; Hsu, D.K.; Pang, M.; Brewer, C.F.; Johnson, P.; Liu, F.T.; Baum, L.G.; Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J. Immunol. 2006, 176, 778-789.
361. Roberts, A.A.; Amano, M.; Felten, C.; Galvan, M.; Sulur, G.; Pinter-Brown, L.; Dobbeling, U.; Burg, G.; Said, J.; Baum, L.G.; Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation. Mod. Pathol. 2003, 16, 543-551.
362. Nguyen, J.T.; Evans, D.P.; Galvan, M.; Pace, K.E.; Leitenberg, D.; Bui, T.N.; Baum, L.G.; CD45 modulates galectin-1-induced T cell death: regulation by expression of core 2 O-glycans. J. Immunol. 2001, 167, 5697-5707.
363. Amano, M.; Galvan, M.; He, J.; Baum, L.G.; The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. J. Biol. Chem. 2003, 278, 7469-7475.
364. Comelli, E.M.; Sutton-Smith, M.; Yan, Q.; Amado, M.; Panico, M.; Gilmartin, T.; Whisenant, T.; Lanigan, C.M.; Head, S.R.; Goldberg, D.; Morris, H.R.; Dell, A.; Paulson, J.C.; Activation of murine CD4+ and CD8+ T lymphocytes leads to dramatic remodeling of N-linked glycans. J. Immunol. 2006, 177, 2431-2440.
365. Chauhan, D.; Li, G.; Podar, K.; Hideshima, T.; Neri, P.; He, D.; Mitsiades, N.; Richardson, P.; Chang, Y.; Schindler, J.; Carver, B.; Anderson, K.C.; A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005, 65, 8350-8358.
366. Streetly, M.J.; Maharaj, L.; Joel, S.; Schey, S.A.; Gribben, J.G.; Cotter, F.E.; GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood 2010, 115, 3939-3948.
367. Grous, J.J.; Redfern, C.H.; Mahadevan, D.; Schindler, J.; GCS-100, a galectin-3 antagonist, in refractory solid tumors: A phase I study. J. Clin. Oncol. (Meeting Abstracts) 2006, 24 Suppl.18S, abstract 13023.
368. Gunning, A.P.; Bongaerts, R.J.; Morris, V.J.; Recognition of galactan components of pectin by galectin-3. Faseb J. 2009, 23, 415-424.
369. Guess, B.W.; Scholz, M.C.; Strum, S.B.; Lam, R.Y.; Johnson, H.J.; Jennrich, R.I.; Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis. 2003, 6, 301-304.
370. Gajewski, T.; Zha, Y.; Thurner, B.; Schuler, G.; Association of gene expression profile in metastatic melanoma and survival to a dendritic cell-based vaccine. J. Clin. Oncol. (Meeting abstracts) 2009, 27 suppl.75S, abstract 9002.
371. Vansteenkiste, J.; Zielinski, M.; Linder, A.; Dahabre, J.; Esteban, E.; Malinowski, W.; Jassem, J.; Passlick, B.; Lehmann, F.; Brichard, V.G.; Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J. Clin.Oncol. (MeetingAstracts) 2007, 25 suppl.78S, abstract 7554.
372. Louahed, J.; Gruselle, O.; Gaulis, S.; Coche, T.; Eggermont, A.M.; Kruit, W.; Dreno, B.; Chiarion Sileni, V.; Lehmann, F.; Brichard, V.G.; Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). J. Clin. Oncol. (Meeting abstracts) 2008, 26 suppl.75S, abstract 9045.
373. Gajewski, T.F.; Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin. Oncol. 2011, 38, 236-242.